Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Industry News

Industry News

What is MLD?

2026-6-16

Metachromatic Leukodystrophy (MLD) is an autosomal recessive inherited disease and one of the most common lysosomal storage disorders. Mutations in the arylsulfatase A (ARSA) or saposin B (SAP-B) gene lead to abnormal accumulation of sulfatides, causing demyelination of brain white matter and peripheral nerves. It is a neurodegenerative metabolic disease. Its typical pathological feature is symmetrical butterfly-shaped lesions in the white matter of the cerebral hemispheres, while subcortical U-fibers are usually preserved.
MLD is mainly divided into late-infantile, juvenile and adult types. In the early stage, peripheral nerve damage is often the first manifestation, accompanied by central nervous system symptoms. Clinical diagnosis requires a combination of urine metachromatic granule detection, ARSA enzyme activity assay and characteristic white matter lesions on brain MRI; brain MRI is especially valuable for excluding pure peripheral neuropathy. Some patients may develop peripheral neuropathy before neurodegenerative symptoms appear.
Currently available treatments include enzyme replacement therapy, hematopoietic stem cell transplantation and gene therapy. Among them, lentiviral-modified hematopoietic stem cell gene therapy (HSCGT) has been proven to have long-term efficacy, delaying disease progression in late-symptomatic juvenile MLD patients and improving their quality of life.


Related News

  • Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?

    2026-10-23

  • Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors

    2026-9-28

  • Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research

    2026-9-28

  • New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction

    2026-9-28

  • Great News! Another Zhongjia Medium Gets FDA DMF Filing

    2026-7-23